Case Studies

J. B. (renal transplant-acute care)
B. W. (liver transplant-acute care)
J. P. (liver transplant-subacute and chronic care)
M. S. (renal transplant-subacute and chronic care)
D. D. (renal transplant-chronic care)
Close This Window



Robert E. Dupuis, David Taber, Amy Fann

Selected References

General Reviews

1. Mitchison HC, Newberger, JM. Medical complications of liver transplantation. Digestive Diseases 1993;11:78-101.

2. Silkensen JR. Long-term complication in renal transplantation. Journal of the American Society of Nephrology 2000;11:582-588.

3. Venkateswara KR. Posttransplant medical complications. Surg Clin North Amer 1998;78(1):113-132.


1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. The New England Journal of Medicine 1998;338(24):1741-1751.

2. Singh N. Infectious diseases in the liver transplant recipient. Seminars in Gastrointestinal Disease 1998;9(3):136-146.

3. Dummer S, Kusne S. Liver transplantation and related infections. Seminars in Respiratory Infections 1993;8(3):191-198.

4. Hibberd PL and Rubin RH. Renal transplantation and related infections. Seminars in Respiratory infections 1993;8(3):216-224.

5. Branten AJ, Beckers PJ Tiggeler RG, Hoitsma AJ. Pneumocystis carinii pneumonia in renal transplant recipients. Nephrology, Dialysis, and Transplantation 1995;10:1194-1197.

6. Couchoud C, Cucherat M, Haugh M, Pouteil-Noble C. Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation. Transplantation 1998;65(5):641-647.

Long-Term Immunosuppressive Strategies

1. Helderman JH, Van Buren DH, Amend WJ, Pirsch JD. Chronic immunosuppression of the renal transplant patient. Journal of the American Society of Nephrology 1994;4(Suppl 1):S2-S9.

2. Matthew TH. Optimal long-term immunotherapy protocols. Transplantation Proceedings 1999;31:1102-1103.

3. McMaster P, Gunson B, Min X, Afonso R, and Bastos J. Liver transplantation: changing goals in immunosuppression. Transplantation Proceedings 1998;30:1819-1821.

4. Riordan SM, Williams R. Tolerance after liver transplantation: does it exist and can immunosuppression be withdrawn? Journal of Hepatology 1999;31:1106-1119.


1. Epstein S, Shane E, Bilezikian JP. Organ transplantation and osteoporosis. Current Opinion in Rheumatology 1995;7:255-261.

2. Coen G. Fracturing osteoporosis after kidney transplantation – what are the options? Nephrology, Dialysis, and Transplantation 1996;11:567-569.

3. McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Digestive Diseases 1994;12:223-231.

4. Anonymous. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis and Rheumatism 1996;39(11):1791-1801.

Post-Transplant Diabetes Mellitus

1. Jindal RM, Sidner RA, Milgram ML. Post-transplant diabetes mellitus: the role of immunosuppression. Drug Safety 1997;16(4):242-257.

2. Jindal RM. Post-transplant diabetes mellitus – a review. Transplantation 1994;12:1289-1298.

3. Navasa M, Bustamante J, Marroni C, Gonzalez E, Hernan A, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. Journal of Hepatology 1996;25:64-71.


1. Savage P, Waxman J. Post-transplant lymphoproliferative disease. Q J Med 1997;90:497-503.

2. Penn I. Tumors after renal and cardiac transplantation. Hematology/Oncology Clinics of North America 1993;7(2):431-445.

3. Sheil AG. Patterns of malignancies following renal transplantation. Transplantation Proceedings 1999;31:1263-1265.

4. Tan-Shalaby J, Tempero M. Malignancies after liver transplantation: a comparative review. Seminars in Liver Disease 1995;15(2):156-164.

Acute/Chronic Rejection

1. Suthanthiran M, Strom TB. Mechanisms and management of acute allograft rejection. Surg Clin North Amer 1998;78:77-94.

2. Ponticelli C. Progression of renal damage in chronic rejection. Kidney International 2000;57(Suppl 75):S62-S70.

3. Jindal RM, Hariharan S. Chronic rejection in kidney transplants: an in-depth review. Nephron 1999;83:13-24.

4. Hayry P, Aavik E, Savolainen H. Mechanisms of chronic rejection. Transplantation Proceedings 1999;31(Suppl 7A):5S-8S.

5. Tiney NL, Kusaka M, Pratschke J, Wilhelm M. Chronic rejection. Transplantation Proceedings 1998;30:1590-1594.

6. Knechtle SJ. Rejection of the liver transplant. Seminars in Gastrointestinal Disease 1998;9(3):126-135.

Recurrence of Disease

1. Matthew TH. Recurrence of disease following renal transplantation. American Journal of Kidney Diseases 1988;12(2):85-96.

2. Reich D, Rothstein K, Manzarbeitia C, Munoz S. Common medical diseases after liver transplantation. Seminars in Gastrointestinal Disease 1998;9(3):110-125.

3. McGory RW, Ishtani MB, Oliveira WM, Stevenson WC, McCullough CS, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996;61(9):1358-1364.

4. Lumbreras C, Colina F, Loinaz MJ, Domingo AF, Domingez P, et al. Clinical, virological, and histological evolution of hepatitis C infection in liver transplant recipients. Clinical Infectious Diseases 1998;26:48-55.


1. Grabenstein JD, Baker JR. Immunization and organ transplantation. Hosp Pharm 1999;339-351.

2. Harmon WE. Immunization practices in transplant recipients. Lierature Scan Transplant 2000;16:4-5.

OTC’s, Medication Non-Adherence, and Drug-Drug and Drug-Herb Interactions

1. Smolinske SC. Dietary Supplement-drug interactions. JAMWA 1999;54(4):191-192.

2. Trotter JF. Drugs that interact with immunosuppressant agents. Seminars in Gastrointestinal Disease 1998;9(3):147-153.

3. Lake KD, Canafax DM. Important interactions of drugs with immunosuppressive agents used in transplant recipients. Journal of Antimicrobial Chemotherapy 1995;36(Suppl B)11-22.

4. Fugh-Berman A. Herb-drug interactions. The Lancet 2000;355:134-138.

5. Miller LG. Herbal medicinals: selected clinical consideration focusing on known or potential drug-herb interactions. Archives of Internal Medicine 1998;158:2200-2211.

6. Ellingson T, Wipke-Tevis D, Livesay T. The use of over-the-counter medication by transplant recipients: a guideline. Journal of Transplant Coordination 1999;9:17-24.

7. Newton SE. Promoting adherence to transplant medication regimens: a review of behavioral analysis. Journal of Transplant Coordination 1999;9:13-16.

Development of a Patient Care Plan and Reimbursement for Provision of Pharmaceutical Services

1. McCallian DJ, Carlstedt BC, Rupp MT. Elements of a pharmaceutical care plan. Journal of the American Pharmaceutical Association 1999;39(1):82-83.

2. Canaday BR, Yarborough PC. Documenting pharmaceutical care: creating a standard. The Annals of Pharmacotherapy 1994;28:1292-1296.

3. Poirier S, Buffington DE, Memoli GA. Billing third party payers for pharmaceutical care services. Journal of the American Pharmaceutical Association 1999;39(1):50-64.

4. Rupp MT. Standardizing documentation for filing pharmaceutical care claims. American Pharmacy 1995;NS35(9):26-30.